Castleman disease is a benign disorder, usually occurring within mediastinum, characterized by proliferation of lymphold tissue. The authors report a rare case of Castleman disease originating from mesenteric root. The tumor was highly vascular, proved by dynamic CT examination and splanchnic angiography.
Angiography ; Giant Lymph Node Hyperplasia* ; Mediastinum

No abstract available.
Chlamydia* ; Fluorescent Antibody Technique, Indirect*

BACKGROUND/AIMS: Although the only therapy of proven benefit for chronic hepatitis C is interferon alpha, the rate of sustained response after treatment with interferon is less than 25%. A 6-month course of combination therapy with interferon and ribavirin was associated with higher rate of long-term response than either interferon or ribavirin alone. Pilot studies suggested that combination of interferon and ursodeoxy-cholic acid (UDCA) resulted in higher biochemical response than interferon alone. We investigated the rates of end of treatment response(ETR) and sustained response(SR) of combination therapy of interferon e2a, ribavirin and UDCA and compared it with interferon a 2a alone. METHODS: Ninty-five naive patients with chronic hepatitis C who have been positive for anti-HCV by 3rd generation EIA and HCV RNA by RT-PCR and had elevated level of ALT over 6 months were included. They were assigned to three groups. Thirty seven patients in group 1 were treated with interferon a 2a (3MU thrice weekly) in combination with ribavirin (600mg/day) and UDCA (600mg/day) for 6 months. Twenty nine patients in group 2 were treated with the same dose of interferon a 2a alone for 6 months. Changes of ALT and HCV RNA were observed over 12 months (average 3029 mos) after the end of treatment in both groups. Twenty nine patients in group 3 were observed over 12 months without antiviral treatment. HCV genotypes were tested by Innop-Lipa in 24 patients in group 1. RESULTS: In group 1, not only ETR (68%) but also 12 month SR rate (54%) was significantly higher than group 2(31%, 21% respectively). There was no difference in relapse rate between two groups. The level of ALT became normalized and HCV RNA negative within 1 month after treatment in most responders in group l. Genotype 1b was associated with lower ETR and SR than non-lb, although not significant stastistically. CONCLUSION: Both the ETR and 12 month SR rate were significantly higher after combination treatment of interferon a 2a, ribavirin and UDCA than interferon e 2a alone in chronic hepatitis C. It is suggested that this combination is preferable to interferon alone in the treatment of naive patients with chronic hepatitis C.
Genotype ; Hepatitis C, Chronic* ; Hepatitis, Chronic* ; Humans ; Interferon-alpha* ; Interferons* ; Recurrence ; Ribavirin* ; RNA

No abstract available.
Cesarean Section* ; Female ; Pregnancy

PURPOSE: To examine the relationship between distance from hepatic capsule to tumor and recurrence among hepatocellular carcinoma patients in whom marginal recurrence was noted after radiofrequency ablation therapy. MATERIALS AND METHODS: Between January 2000 and December 2001, hepatocellular carcinoma patients with a tumor 5 cm or less in size and located 2 cm or less from the hepatic capsule underwent radiofrequency ablation therapy. We subsequently selected 37 patients (41 tumors) in whom immediate CT demonstrated complete tumor ablation and follow-up CT showed marginal recurrence. Tumors were grouped according to their distance from the hepatic capsule: Group I, adhered to the capsule; Group II, less than 1 cm from it; Group III, 1-2 cm distant. Of the 41 tumors, 22 were assigned to Group I, six to Group II, and 13 to Group III. Mean tumor size was 3.2 cm, and inter-group variation was small (Group I, 3.3 cm; Group II, 2.9 cm; Group III, 3.1 cm). Follow-up CT was used to determine marginal recurrence, and for inter-group comparison and the assessment of statistical significance, the t test was employed. RESULTS: Marginal recurrence was noted at mean 5.5 months (2.7 months in Group I, 3.0 months in Group II, and 10.5 months in Group III). The t test revealed significant difference between Group I and III (p<0.0001) but not between Groups I and II, or II and III. If '1 cm from hepatic capsule' was the criterion for classification, and Group I and II were combined and compared with Group III, there was significant difference between the two groups (<0.0001). CONCLUSION: Tumors which adhered to the hepatic capsule or were less than 1 cm from it recurred sooner than those situated 1-2 cm away.
Carcinoma, Hepatocellular* ; Catheter Ablation* ; Classification ; Follow-Up Studies ; Humans ; Recurrence*

Trichogenic tumors are very rare and described as cutaneous neoplasms probably derived from hair germ which develops into hair follicles. We report a case of trichoblastic fibroma on the left parietal scalp of a 45-year-old man. The lesion was a solitary, firm, non-tender, 2×2cm subcutaneous nodule. The histopathological study showed a well circumscribed dermal tumor composed of abundant basophilic palisading basaloid lobules with some keratinous cysts, hair follicle differentiation and fibroblastic stroma.
Basophils ; Fibroblasts ; Fibroma* ; Hair ; Hair Follicle ; Humans ; Middle Aged ; Rabeprazole ; Scalp

No abstract available.
Hepatitis B* ; Hepatitis*

BACKGROUND: To evaluate the radiological, clinical results in patients with open distal tibia factures, who were treated with a staged treatment protocol using the lateral minimally invasive plate osteosynthesis (MIPO) technique. METHODS: From January 2007 to June 2009, 10 patients with open distal tibia fractures (Gustilo-Anderson classification II, 3; IIIA, 1; IIIB, 6) were treated using a staged treatment protocol. The initial debridement and application of an external fixator were performed within 24 hours and the mean interval from injury to definitive surgical treatment was 15 days (range, 6 to 52 days). Eight weeks later, an additional bone graft was performed in 3 patients. The follow-up duration was more than 1 year. RESULTS: The mean fracture healing time was 21 weeks (range, 17 to 28 weeks), and the average Iowa ankle rating score was 84.5 points. At the last follow-up, there was no non-union, angular deformity > 5degrees, shortening > 10 mm or infection. In 10 patients, 2 patients had a superficial wound infection, and another 2 patients showed limitation of ankle joint motion. CONCLUSIONS: This staged treatment protocol using a lateral MIPO technique is a useful alternative method for achieving high functional recovery with good healing and low complication rates in patients with an open distal tibia fracture.
Adult ; Aged ; Aged, 80 and over ; Ankle Injuries/*surgery ; Bone Transplantation ; Clinical Protocols ; Debridement ; External Fixators ; Female ; Fracture Fixation, Internal/*methods ; Fractures, Open/*surgery ; Humans ; Male ; Middle Aged ; Negative-Pressure Wound Therapy ; Therapeutic Irrigation ; Tibial Fractures/*surgery ; Treatment Outcome

No abstract available.
Leiomyoma*

BACKGROUND/AIMS: Chronic hepatitis C virus (HCV) infection is often associated with extrahepatic autoimmune disease, and autoantibodies such as anti-nuclear antibody (ANA) or anti-smooth muscle antibody (ASA). The presence of autoantibodies may make discrimination between chronic hepatitis C with autoimmune features and type 1 autoimmune hepatitis difficult. We studied the prevalence of autoantibodies in patients with chronic HCV infection and their clinical significance. MATERIALS AND METHODS: ANA, ASA, anti-mitochondrial antibody (AMA), anti-microsomal antibody (AmA), rheumatoid factor (RF), anti-cardiolipin antibody (aCL) and lupus anti-coagulant (LA) were tested in 116 patients (80 chronic hepatitis C, 36 liver cirrhosis). Genotypes of HCV were determined in 25 patients by INNO LiPA. RESULTS: The overall prevalence of autoantibody was 65.5%. The most common autoantibody was aCL (34.5%), followed by ANA (25%), RF (18%), LA (15.5%), ASA (6.9%), anti-microsomal antibody (6%) and AMA (1%). The positive rate of either ANA or ASA was 30.2%, but both were positive in 1.7% only. There was no difference in the demographic features, biochemistry, HCV genotypes and disease status between autoantibody-positive and autoantibody-negative patients. CONCLUSIONS: Autoantibodies were commonly found in patients with chronic HCV infection. But, the presence of autoantibodies may be a non-specific finding in chronic hepatitis C infection without clinical significance.
Autoantibodies* ; Autoimmune Diseases ; Biochemistry ; Discrimination (Psychology) ; Genotype ; Hepacivirus ; Hepatitis C, Chronic* ; Hepatitis, Autoimmune ; Hepatitis, Chronic* ; Humans ; Liver ; Prevalence* ; Rheumatoid Factor